We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,680

PTAB Denies Priority Claim, Has No Affinity for “Antibody Rule”
  • McDermott Will & Emery
  • USA
  • July 26 2016

Addressing enablement and written description issues in the context of a priority challenge, the Patent Trial and Appeal Board (PTAB or Board) found


Federal Circuit Rubberstamps 50-Year-Old Practice to Save 10,000 Continuation Patents
  • McDermott Will & Emery
  • USA
  • July 26 2016

Addressing the question of precisely when a continuation application must be filed in order to be entitled to its parent application's filing date


CBM Decisions Show Limits of Enfish
  • McDermott Will & Emery
  • USA
  • July 26 2016

Recent covered business method (CBM) review decisions by the Patent Trial and Appeal Board (PTAB or Board) demonstrate that the US Court of Appeals


In First Set of Post-Grant Review Decisions, PTAB Strikes Down Patents Based on Alice
  • McDermott Will & Emery
  • USA
  • July 26 2016

Addressing for the first time the issue of patent validity in the context of an America Invents Act post-grant review, the Patent Trial and Appeal


Merck’s Damages Award for Infringement Thwarted by Gilead’s Equitable Defenses of Unclean Hands
  • McDermott Will & Emery
  • USA
  • July 19 2016

In this ongoing, multi-faceted case, the parties recently received the US District Court for the Northern District of California's rulings on whether


District Court of New Jersey Boots Hospira’s Personal Jurisdiction and Rule 12(b)(6) Motions
  • McDermott Will & Emery
  • USA
  • July 19 2016

Relying on the US Court of Appeals for the Federal Circuit's recent decision in Acorda Therapeutics Inc. v. Mylan Pharmaceuticals, Inc., Nos. 15-1456


Fixed-Combination Drug Products Eligible for Five-Year Exclusivity
  • McDermott Will & Emery
  • USA
  • July 19 2016

Addressing whether the US Food and Drug Administration's (FDA) denial of Ferring Pharmaceutical's application for marketing exclusivity was arbitrary


Product sans Problem Can Be Obvious Even though a Source of the Problem Is Non-Obvious
  • McDermott Will & Emery
  • USA
  • July 19 2016

Addressing obviousness in the context of a non-obvious problem source, the US Court of Appeals for the Federal Circuit affirmed the US District Court


180-Day Notice Period for Biosimilar Approval Is Always Mandatory and Enforceable by Injunction
  • McDermott Will & Emery
  • USA
  • July 19 2016

A year after analyzing the patent dance and notice requirements of the Biologics Price Competition and Innovation Act (BPCIA) in Amgen Inc. v. Sandoz


Federal Circuit Rejects Argument that Claim Is Novel because Composition Exhibits ‘Pharmaceutically Effective Absorption’
  • McDermott Will & Emery
  • USA
  • July 19 2016

Where a claim was distinguished from the prior art only because it contained a limitation requiring "pharmaceutically effective absorption," the US